ALX ONCOLOGY HLDGS INC's ticker is ALXO and the CUSIP is 00166B105. A total of 98 filers reported holding ALX ONCOLOGY HLDGS INC in Q2 2022. The put-call ratio across all filers is 0.01 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $1,103,404 | -40.0% | 98,960 | -19.8% | 0.00% | -42.9% |
| Q4 2023 | $1,837,724 | +161.0% | 123,420 | -15.9% | 0.01% | +133.3% |
| Q3 2023 | $704,050 | -36.1% | 146,677 | 0.0% | 0.00% | -25.0% |
| Q2 2023 | $1,101,544 | +69.8% | 146,677 | +2.2% | 0.00% | +33.3% |
| Q1 2023 | $648,652 | -61.6% | 143,507 | -4.3% | 0.00% | -62.5% |
| Q4 2022 | $1,689,734 | +16.9% | 149,932 | -0.8% | 0.01% | +14.3% |
| Q3 2022 | $1,446,000 | +80.5% | 151,112 | +52.7% | 0.01% | +75.0% |
| Q2 2022 | $801,000 | +172.4% | 98,964 | +2387.2% | 0.00% | +300.0% |
| Q3 2021 | $294,000 | – | 3,979 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 9,699,925 | $163,929,000 | 36.34% |
| Logos Global Management LP | 3,011,352 | $50,892,000 | 6.60% |
| Vivo Capital, LLC | 4,220,048 | $71,319,000 | 4.91% |
| Samsara BioCapital, LLC | 262,786 | $4,441,000 | 1.12% |
| Cormorant Asset Management, LP | 712,079 | $12,034,000 | 0.92% |
| Pier Capital, LLC | 394,443 | $6,666,000 | 0.85% |
| Redmile Group, LLC | 772,397 | $13,054,000 | 0.41% |
| Artal Group S.A. | 500,000 | $8,450,000 | 0.35% |
| Nan Fung Group Holdings Ltd | 41,950 | $709,000 | 0.34% |
| Orbimed Advisors | 621,700 | $10,507,000 | 0.17% |